| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | ANANEO THERAPEUTICS INC | 885 3RD AVE | NEW YORK | NY | 10022-4834 | NEW YORK | USA | R41CA275627 | Validating novel DNA repair deficient cancer therapy targets and small molecule compounds | 000 | 1 | NIH | 12/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ANANEO THERAPEUTICS INC. | 885 3RD AVE FL 20 | NEW YORK | NY | 10022-4834 | NEW YORK | USA | R41CA275627 | Validating novel DNA repair deficient cancer therapy targets and small molecule compounds | 000 | 1 | NIH | 10/31/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $398,917 ) |
| | 2022 | 2022 | ANANEO THERAPEUTICS INC. | 885 3RD AVE FL 20 | NEW YORK | NY | 10022-4834 | NEW YORK | USA | R41CA275627 | Validating novel DNA repair deficient cancer therapy targets and small molecule compounds | 000 | 1 | NIH | 8/8/2022 | $398,917 |
|
|
